Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
European Commission approves Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types January 23, 2024
European Commission Approves KRAZATI (adagrasib) for Patients with Advanced NSCLC with a KRASG12C Mutation January 17, 2024
FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer January 17, 2024
European Commission Approves KEYTRUDA + Chemotherapy for New 1L Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer January 4, 2024
FDA Approves WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 19, 2023
FDA Approves Expanded Indication for KEYTRUDA Plus Padcev for 1L Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer December 19, 2023
Abecma Approved in Earlier Lines of Therapy for Patients with R/R Multiple Myeloma in Japan December 11, 2023
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer December 4, 2023
FDA Approves Augtyro™ (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive NSCLC December 4, 2023
Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer November 29, 2023
European Commission Approves BRUKINSA® (zanubrutinib) for the Treatment of R/R Follicular Lymphoma November 29, 2023
FDA Approves KEYTRUDA + Chemotherapy as 1L Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Adenocarcinoma November 29, 2023
FDA Approves KEYTRUDA + Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer November 7, 2023
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC October 31, 2023
FDA approves LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) October 31, 2023
FDA Approves KEYTRUDA for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemo as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery October 25, 2023
European Commission Approves KEYTRUDA as Adjuvant Treatment for Adults With NSCLC at High Risk of Recurrence Following Complete Resection & Platinum-Based Chemo October 25, 2023
EC Approves ADCETRIS + AVD combo for Adult Patients with 1L CD30+ Stage III Hodgkin Lymphoma October 25, 2023
FDA Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma October 25, 2023
